Pagliarulo, Vincenzo; Bracarda, Sergio; Eisenberger, Mario A; Mottet, Nicolas; Schröder, Fritz H; Sternberg, Cora N; Studer, Urs E (2012). Contemporary role of androgen deprivation therapy for prostate cancer. European urology, 61(1), pp. 11-25. Amsterdam: Elsevier 10.1016/j.eururo.2011.08.026
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S0302283811008943-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (256kB) | Request a copy |
Androgen deprivation therapy (ADT) for prostate cancer (PCa) represents one of the most effective systemic palliative treatments known for solid tumors. Although clinical trials have assessed the role of ADT in patients with metastatic and advanced locoregional disease, the risk-benefit ratio, especially in earlier stages, remains poorly defined. Given the mounting evidence for potentially life-threatening adverse effects with short- and long-term ADT, it is important to redefine the role of ADT for this disease.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology |
UniBE Contributor: |
Studer, Urs |
ISSN: |
0302-2838 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:20 |
Last Modified: |
28 Jun 2023 14:44 |
Publisher DOI: |
10.1016/j.eururo.2011.08.026 |
PubMed ID: |
21871711 |
Web of Science ID: |
000297861800006 |
BORIS DOI: |
10.48350/6829 |
URI: |
https://boris.unibe.ch/id/eprint/6829 (FactScience: 211859) |
Actions (login required)
 |
Edit item |